Details of Disease

General Information of Disease (ID: DIS6FLUM)

Disease Name	Pulmonary tuberculosis
Synonyms	lung TB; pulmonary TB; lung tuberculosis
Disease Class	1B10-1B12: Tuberculosis
Definition	A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.
Disease Hierarchy	DISGGAGJ: Respiratory disease DIS2YIMD: Tuberculosis DIS6FLUM: Pulmonary tuberculosis
ICD Code	ICD-11 ICD-11: 1B10.Z Expand ICD-11 '1B10.Z
Disease Identifiers	MONDO ID MONDO_0006052 MESH ID D014397 UMLS CUI C0041327 MedGen ID 11947 HPO ID HP:0032262 SNOMED CT ID 154283005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aminosalicylic Acid	DMENSL5	Approved	Small molecular drug	[1]
Bedaquiline	DM3906J	Approved	Small molecular drug	[2]
Capreomycin	DMNZBRY	Approved	Small molecular drug	[3]
Cycloserine	DMT1I52	Approved	Small molecular drug	[4]
Ethambutol	DMR87LC	Approved	Small molecular drug	[5]
Ethionamide	DM8K3EI	Approved	Small molecular drug	[6]
Isoniazid	DM5JVS3	Approved	Small molecular drug	[7]
Phenyl Aminosalicylate	DMRU8GX	Approved	Small molecular drug	[5]
Potassium Aminosalicylate	DMNZQXF	Approved	Small molecular drug	[5]
Pyrazinamide	DM4IF32	Approved	Small molecular drug	[8]
Rifampicin	DM5DSFZ	Approved	NA	[9]
Rifapentine	DMCHV4I	Approved	Small molecular drug	[10]
Streptomycin	DME1LQN	Approved	Small molecular drug	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 Drug(s)

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BVL-GSK098	DMNUYML	Phase 2	Small molecule	[12]
Delpazolid	DMGUQMJ	Phase 2	Small molecular drug	[13]
TBI-166	DMMBDIH	Phase 2	Small molecule	[14]
TBAJ-876	DMVVWC8	Phase 1	Small molecule	[15]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
L-serine	DM6WPIS	Investigative	Small molecular drug	[16]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 44 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CRAT	TTC8M31	Limited	Biomarker	[17]
MBP	TT2RY5P	Limited	Biomarker	[18]
SELL	TT2IYXF	Limited	Biomarker	[19]
SLC1A1	TTG2A6F	Limited	Genetic Variation	[20]
SLC7A1	TT4S150	Limited	Biomarker	[17]
TLR6	TTWRI8V	Limited	Genetic Variation	[21]
TREM1	TTHZQP0	Limited	Biomarker	[22]
TRPV6	TTBK14N	Limited	Biomarker	[17]
CAMP	TTULOB6	moderate	Altered Expression	[23]
CCL3	TT8I4WB	moderate	Genetic Variation	[24]
GEM	TTAZF9M	moderate	Genetic Variation	[25]
IFNGR2	TT13TL0	moderate	Genetic Variation	[26]
IFNL1	TTM624L	moderate	Biomarker	[27]
IL17F	TT2B6PS	moderate	Biomarker	[28]
SLC39A6	TTZN1CF	moderate	Altered Expression	[29]
TCIRG1	TTVRN05	moderate	Genetic Variation	[30]
TIRAP	TTKU0LS	moderate	Genetic Variation	[31]
TST	TT51OTS	moderate	Biomarker	[32]
CA12	TTSYM0R	Strong	Genetic Variation	[33]
CCL5	TT9DWLC	Strong	Genetic Variation	[34]
CD209	TTBXIM9	Strong	Genetic Variation	[35]
CEL	TTTRNQW	Strong	Altered Expression	[36]
CFP	TTLA0VS	Strong	Biomarker	[19]
CXCL10	TTQOVYA	Strong	Altered Expression	[37]
CXCL9	TTWE5PB	Strong	Altered Expression	[38]
EREG	TTYSB89	Strong	Altered Expression	[39]
HLA-A	TTHONFT	Strong	Genetic Variation	[40]
HLA-DQB2	TTL7VOU	Strong	Biomarker	[41]
HPD	TT8DSFC	Strong	Biomarker	[42]
IL17D	TTC5LTG	Strong	Genetic Variation	[43]
IL20	TTNZMY2	Strong	Biomarker	[44]
IL23R	TT6H4QR	Strong	Genetic Variation	[45]
IL5	TTPREZD	Strong	Biomarker	[46]
IRAK3	TTBPJOK	Strong	Altered Expression	[47]
MC3R	TTNI91K	Strong	Genetic Variation	[48]
MMP1	TTMX39J	Strong	Biomarker	[49]
MRC1	TTKV8W5	Strong	Biomarker	[50]
NOD2	TTYPUHA	Strong	Genetic Variation	[51]
P2RX1	TTJW7B3	Strong	Biomarker	[52]
PTBP1	TTWMX0U	Strong	Biomarker	[53]
TAP1	TT7JZI8	Strong	Genetic Variation	[54]
TLR1	TTW14D0	Strong	Genetic Variation	[55]
TLR2	TTY7ZHS	Strong	Genetic Variation	[56]
TLR8	TT8CWFK	Strong	Genetic Variation	[57]
------------------------------------------------------------------------------------


⏷ Show the Full List of 44 DTT(s)

This Disease Is Related to 9 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC34A1	DT42EWA	Limited	Genetic Variation	[58]
SLC7A2	DTWY9RT	Limited	Biomarker	[59]
SLC30A1	DT1BO38	moderate	Altered Expression	[29]
SLC39A1	DTLWPXS	moderate	Altered Expression	[29]
SLC39A2	DTL8VXO	moderate	Altered Expression	[29]
SLC39A8	DTLPQGT	moderate	Altered Expression	[29]
SLC11A1	DT650XW	Strong	Biomarker	[60]
SLC14A2	DT8QC7K	Strong	Genetic Variation	[61]
SLC27A5	DT0TQS3	Strong	Altered Expression	[36]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DTP(s)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SAT1	DEMWO83	moderate	Biomarker	[62]
NAT2	DER7TA0	Strong	Genetic Variation	[63]
------------------------------------------------------------------------------------

This Disease Is Related to 68 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ASAP1	OT4DLRYY	Limited	Biomarker	[64]
CCL4L2	OTDBSXOU	Limited	Genetic Variation	[24]
CDX2	OTCG4TSY	Limited	Genetic Variation	[65]
DUSP14	OTGODFCR	Limited	Altered Expression	[66]
FCN2	OTTHJBKZ	Limited	Genetic Variation	[67]
GIT1	OTHO92S5	Limited	Biomarker	[17]
GIT2	OTQ2EQJ1	Limited	Biomarker	[59]
GZMA	OT43R33L	Limited	Biomarker	[68]
HCST	OTILCB4K	Limited	Biomarker	[69]
IRGM	OTKD3O5Z	Limited	Genetic Variation	[70]
NFKBIL1	OTYFTPS0	Limited	Genetic Variation	[71]
PDE6B	OTOJMB1V	Limited	Biomarker	[72]
SERPINA3	OT9BP2S0	Limited	Biomarker	[73]
SFTPA1	OT87XL1U	Limited	Genetic Variation	[74]
SFTPA2	OT6SFOMU	Limited	Genetic Variation	[74]
SMIM10L2B	OT04IG2N	Limited	Biomarker	[75]
TRPV5	OTWF4L0U	Limited	Biomarker	[59]
AGMO	OTGMAHAT	moderate	Genetic Variation	[76]
BANF2	OT03L8AN	moderate	Biomarker	[77]
C4BPB	OTJ70B0K	moderate	Biomarker	[78]
CLEC4E	OT7P8ICY	moderate	Genetic Variation	[79]
CTSZ	OTSCX2LL	moderate	Genetic Variation	[80]
FAM76B	OT4RG5U7	moderate	Genetic Variation	[81]
FBL	OTRODIE5	moderate	Biomarker	[78]
FLNB	OTPCOYL6	moderate	Genetic Variation	[54]
KIR2DS3	OT3PSLDL	moderate	Biomarker	[25]
KIR3DL1	OTPOSXFX	moderate	Genetic Variation	[25]
NXF1	OTEFHXG6	moderate	Genetic Variation	[54]
ORM1	OTZKSBRE	moderate	Biomarker	[73]
PIWIL1	OT7CRGZ3	moderate	Biomarker	[82]
PIWIL4	OTDA9MY0	moderate	Biomarker	[82]
SEC14L2	OTJST64D	moderate	Genetic Variation	[54]
SHOC1	OTP51XIP	moderate	Altered Expression	[29]
THEMIS	OTXODBXJ	moderate	Biomarker	[83]
TOX	OTE8BL5Z	moderate	Genetic Variation	[84]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[85]
CARD8	OTXXZYWU	Strong	Genetic Variation	[86]
CCL4	OT6B8P25	Strong	Altered Expression	[87]
CCN6	OTRFHQ2Z	Strong	Biomarker	[42]
CD81	OTQFXNAZ	Strong	Altered Expression	[88]
GNLY	OTZJKA8C	Strong	Biomarker	[89]
HLA-DPA1	OT7OG7Y2	Strong	Genetic Variation	[41]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[41]
HPX	OT14T7Q1	Strong	Biomarker	[90]
IL12RB1	OTM1IJO2	Strong	Genetic Variation	[91]
IL17B	OTS86H50	Strong	Biomarker	[44]
IL27	OTIS3OF8	Strong	Genetic Variation	[43]
INTS4	OT5JQ913	Strong	Genetic Variation	[92]
ITIH4	OT460OO1	Strong	Genetic Variation	[93]
LAMP3	OTN0XL3W	Strong	Biomarker	[94]
LSAMP	OTYXVQX2	Strong	Biomarker	[94]
MARCO	OT0NW2Q0	Strong	Genetic Variation	[95]
MASP1	OTWWCNZP	Strong	Genetic Variation	[96]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[97]
MYDGF	OT9HRPL6	Strong	Genetic Variation	[43]
NCAPG2	OTZYENKO	Strong	Biomarker	[37]
P2RX2	OT0LF34A	Strong	Biomarker	[52]
PARP9	OT7K4494	Strong	Altered Expression	[36]
PTBP2	OTF4S7NE	Strong	Biomarker	[53]
PTPN22	OTDCNTC3	Strong	Genetic Variation	[98]
RBM45	OTWTHD77	Strong	Biomarker	[40]
SIGLEC1	OTNWSQA9	Strong	Genetic Variation	[99]
SMURF1	OT5UIZR8	Strong	Biomarker	[100]
TAP2	OTWSYFI7	Strong	Genetic Variation	[54]
TOLLIP	OTYEO4NR	Strong	Genetic Variation	[101]
CCL1	OT23NON8	Definitive	Genetic Variation	[102]
LYPD4	OTYNO8BS	Definitive	Biomarker	[103]
NSMAF	OTYNVZ23	Definitive	Genetic Variation	[104]
------------------------------------------------------------------------------------


⏷ Show the Full List of 68 DOT(s)

References

1	Aminosalicylic acid FDA Label
2	Bedaquiline FDA Label
3	Capreomycin FDA Label
4	Cycloserine FDA Label
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Ethionamide FDA Label
7	Isoniazid FDA Label
8	Pyrazinamide FDA Label
9	Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD013359.
10	Rifapentine FDA Label
11	Streptomycin FDA Label
12	ClinicalTrials.gov (NCT05473195) A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis. U.S.National Institutes of Health.
13	ClinicalTrials.gov (NCT02836483) A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK. U.S. National Institutes of Health.
14	ClinicalTrials.gov (NCT04670120) Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With Pyrifazimine (TBI-166). U.S.National Institutes of Health.
15	ClinicalTrials.gov (NCT04493671) A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose With a Food Effect Cohort and Multiple Ascending Dose Study Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects. U.S.National Institutes of Health.
16	Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model. Sci Rep. 2023 May 26;13(1):8551.
17	Determination of drug susceptibility patterns and genotypes of Mycobacterium tuberculosis isolates from Kanpur district, North India.Infect Genet Evol. 2011 Mar;11(2):469-75. doi: 10.1016/j.meegid.2010.12.010. Epub 2011 Jan 13.
18	Assessment of the serodiagnostic potential of nine novel proteins from Mycobacterium tuberculosis.FEMS Microbiol Lett. 2001 Apr 20;198(1):31-6. doi: 10.1111/j.1574-6968.2001.tb10615.x.
19	Detection of Mycobacterium tuberculosis lipoarabinomannan and CFP-10 (Rv3874) from urinary extracellular vesicles of tuberculosis patients by immuno-PCR.Pathog Dis. 2019 Jul 1;77(5):ftz049. doi: 10.1093/femspd/ftz049.
20	SLC11A1 (NRAMP1) but not SLC11A2 (NRAMP2) polymorphisms are associated with susceptibility to tuberculosis in a high-incidence community in South Africa.Int J Tuberc Lung Dis. 2004 Dec;8(12):1464-71.
21	Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India.Tuberculosis (Edinb). 2010 Sep;90(5):306-10. doi: 10.1016/j.tube.2010.08.001. Epub 2010 Aug 24.
22	Activation and Regulation of Blood V2 T Cells Are Amplified by TREM-1(+) during Active Pulmonary Tuberculosis.J Immunol. 2018 Mar 1;200(5):1627-1638. doi: 10.4049/jimmunol.1700785. Epub 2018 Feb 2.
23	Status of cathelicidin IL-37, cytokine TNF, and vitamin D in patients with pulmonary tuberculosis.J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2):321-325.
24	CCL2, CCL3 and CCL4 gene polymorphisms in pulmonary tuberculosis patients of South India.Int J Immunogenet. 2014 Apr;41(2):98-104. doi: 10.1111/iji.12085. Epub 2013 Sep 3.
25	Potential implication of activating killer cell immunoglobulin-like receptor and HLA in onset of pulmonary tuberculosis.Scand J Immunol. 2012 Nov;76(5):491-6. doi: 10.1111/j.1365-3083.2012.02762.x.
26	Association of IFNGR2 gene polymorphisms with pulmonary tuberculosis among the Vietnamese.Hum Genet. 2012 May;131(5):675-82. doi: 10.1007/s00439-011-1112-8. Epub 2011 Nov 6.
27	Diminished circulating plasma and elevated lymph node culture supernatant levels of IL-10 family cytokines in tuberculous lymphadenitis.Cytokine. 2018 Nov;111:511-517. doi: 10.1016/j.cyto.2018.05.027. Epub 2018 Jun 2.
28	Diminished type 1 and type 17 cytokine expressing - Natural killer cell frequencies in tuberculous lymphadenitis.Tuberculosis (Edinb). 2019 Sep;118:101856. doi: 10.1016/j.tube.2019.101856. Epub 2019 Aug 6.
29	Up-regulation of Slc39A2(Zip2) mRNA in peripheral blood mononuclear cells from patients with pulmonary tuberculosis.Mol Biol Rep. 2013 Aug;40(8):4979-84. doi: 10.1007/s11033-013-2598-z. Epub 2013 May 18.
30	Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia.Genes Immun. 2014 Sep;15(6):370-7. doi: 10.1038/gene.2014.28. Epub 2014 Jun 5.
31	TIRAP rs8177374 gene polymorphism increased the risk of pulmonary tuberculosis in Zahedan, southeast Iran.Asian Pac J Trop Med. 2014 Jun;7(6):451-5. doi: 10.1016/S1995-7645(14)60073-0.
32	Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting.PLoS One. 2017 Jan 6;12(1):e0169539. doi: 10.1371/journal.pone.0169539. eCollection 2017.
33	Association of polymorphisms in IL-12/IFN-gamma pathway genes with susceptibility to pulmonary tuberculosis in Indonesia.Tuberculosis (Edinb). 2007 Jul;87(4):303-11. doi: 10.1016/j.tube.2007.02.001. Epub 2007 Mar 27.
34	Age-Specific Association of CCL5 Gene Polymorphism with Pulmonary Tuberculosis: A Case-Control Study.Genet Test Mol Biomarkers. 2018 May;22(5):281-287. doi: 10.1089/gtmb.2017.0250. Epub 2018 Apr 2.
35	The association between CD209 gene polymorphisms and pulmonary tuberculosis susceptibility: a meta-analysis.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12437-45. eCollection 2015.
36	Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis.Am J Respir Crit Care Med. 2018 Jul 15;198(2):245-255. doi: 10.1164/rccm.201710-2102OC.
37	IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting.Sci Rep. 2019 Mar 7;9(1):3871. doi: 10.1038/s41598-019-40458-0.
38	Cytokine and soluble adhesion molecule profiles and biomarkers for treatment monitoring in Re-treated smear-positive patients with pulmonary tuberculosis.Cytokine. 2018 Aug;108:9-16. doi: 10.1016/j.cyto.2018.03.009. Epub 2018 Mar 16.
39	Polymorphism in the EREG gene confers susceptibility to tuberculosis.BMC Med Genet. 2019 Jan 11;20(1):7. doi: 10.1186/s12881-018-0729-z.
40	Genetic polymorphism of human leucocyte antigen and susceptibility to multidrug-resistant and rifampicin-resistant tuberculosis in Han Chinese from Hubei Province.Int J Immunogenet. 2018 Feb;45(1):8-21. doi: 10.1111/iji.12352. Epub 2017 Dec 8.
41	Association of human leukocyte antigens-DQB2/DPA1/DPB1 polymorphism and pulmonary tuberculosis in the Chinese Uygur population.Mol Genet Genomic Med. 2019 Mar;7(3):e544. doi: 10.1002/mgg3.544. Epub 2019 Jan 1.
42	Influence of HLA-DR and -DO phenotypes on tuberculin reactive status in pulmonary tuberculosis patients.Tuber Lung Dis. 1996 Aug;77(4):369-73. doi: 10.1016/s0962-8479(96)90104-5.
43	Association between polymorphisms of cytokine genes and secretion of IL-12p70, IL-18, and IL-27 by dendritic cells in patients with pulmonary tuberculosis.Tuberculosis (Edinb). 2019 Mar;115:56-62. doi: 10.1016/j.tube.2019.02.003. Epub 2019 Feb 6.
44	Modulation of Th1/Tc1 and Th17/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines.Cytokine. 2018 Aug;108:190-196. doi: 10.1016/j.cyto.2018.04.005. Epub 2018 Apr 21.
45	The variations of IL-23R are associated with susceptibility and severe clinical forms of pulmonary tuberculosis in Chinese Uygurs.BMC Infect Dis. 2015 Dec 1;15:550. doi: 10.1186/s12879-015-1284-2.
46	HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses.J Virol. 2019 Feb 19;93(5):e01728-18. doi: 10.1128/JVI.01728-18. Print 2019 Mar 1.
47	IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis.BMC Microbiol. 2017 Aug 23;17(1):185. doi: 10.1186/s12866-017-1095-2.
48	Association analysis of melanocortin 3 receptor polymorphisms with the risk of pulmonary tuberculosis.Lung. 2014 Dec;192(6):857-62. doi: 10.1007/s00408-014-9625-2. Epub 2014 Jul 27.
49	Integrin 21 Expression Regulates Matrix Metalloproteinase-1-Dependent Bronchial Epithelial Repair in Pulmonary Tuberculosis.Front Immunol. 2018 Jun 22;9:1348. doi: 10.3389/fimmu.2018.01348. eCollection 2018.
50	Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis.Sci Rep. 2018 Sep 3;8(1):13129. doi: 10.1038/s41598-018-31565-5.
51	NOD2 polymorphisms and pulmonary tuberculosis susceptibility: a systematic review and meta-analysis.Int J Biol Sci. 2013 Dec 28;10(1):103-8. doi: 10.7150/ijbs.7585.
52	Expression and function of the purinergic receptor P2X7 in patients with pulmonary tuberculosis.Clin Exp Immunol. 2006 Nov;146(2):253-61. doi: 10.1111/j.1365-2249.2006.03213.x.
53	Diagnostic Accuracy of Interleukin-27 in Bronchoalveolar Lavage Fluids for Pulmonary Tuberculosis.Infect Drug Resist. 2019 Dec 2;12:3755-3763. doi: 10.2147/IDR.S231215. eCollection 2019.
54	Association of TAP1 and TAP2 Gene Polymorphisms with Susceptibility to Pulmonary Tuberculosis.Iran J Allergy Asthma Immunol. 2016 Feb;15(1):62-8.
55	Toll-like Receptor 1 Polymorphisms Increased the Risk of Pulmonary Tuberculosis in an Iranian Population Sample.Biomed Environ Sci. 2016 Nov;29(11):825-828. doi: 10.3967/bes2016.110.
56	TLR2 Arg753Gln Gene Polymorphism Associated with Tuberculosis Susceptibility: An Updated Meta-Analysis.Biomed Res Int. 2019 Jan 13;2019:2628101. doi: 10.1155/2019/2628101. eCollection 2019.
57	Genetic variation in TLR pathway and the risk of pulmonary tuberculosis in a Moldavian population.Infect Genet Evol. 2019 Mar;68:84-90. doi: 10.1016/j.meegid.2018.12.005. Epub 2018 Dec 5.
58	P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis.Clin Exp Immunol. 2007 Jun;148(3):469-77. doi: 10.1111/j.1365-2249.2007.03359.x.
59	Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.Sci Rep. 2017 Jun 13;7(1):3354. doi: 10.1038/s41598-017-03514-1.
60	3'UTR polymorphisms in NRAMP1 are associated with the susceptibility to pulmonary tuberculosis: A MOOSE-compliant meta-analysis.Medicine (Baltimore). 2019 Jun;98(23):e15955. doi: 10.1097/MD.0000000000015955.
61	Interleukin-12B & interleukin-10 gene polymorphisms in pulmonary tuberculosis.Indian J Med Res. 2007 Aug;126(2):135-8.
62	Clinical diagnostic value of simultaneous amplification and testing for the diagnosis of sputum-scarce pulmonary tuberculosis.BMC Infect Dis. 2017 Aug 5;17(1):545. doi: 10.1186/s12879-017-2647-7.
63	NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.Eur J Clin Pharmacol. 2013 May;69(5):1091-101. doi: 10.1007/s00228-012-1429-9. Epub 2012 Nov 14.
64	Susceptibility to tuberculosis is associated with variants in the ASAP1 gene encoding a regulator of dendritic cell migration.Nat Genet. 2015 May;47(5):523-527. doi: 10.1038/ng.3248. Epub 2015 Mar 16.
65	Influence of Cdx2 and TaqI Gene Variants on Vitamin D(3) Modulated Intracellular Chemokine Positive T-Cell Subsets in Pulmonary Tuberculosis.Clin Ther. 2017 May;39(5):946-957. doi: 10.1016/j.clinthera.2017.04.003. Epub 2017 May 2.
66	Influence of the polymorphism of the DUSP14 gene on the expression of immune-related genes and development of pulmonary tuberculosis.Genes Immun. 2016 Jun;17(4):207-12. doi: 10.1038/gene.2016.11. Epub 2016 Mar 3.
67	Association of the FCN2 Gene Single Nucleotide Polymorphisms with Susceptibility to Pulmonary Tuberculosis.PLoS One. 2015 Sep 17;10(9):e0138356. doi: 10.1371/journal.pone.0138356. eCollection 2015.
68	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.Exp Mol Pathol. 2009 Feb;86(1):69-73. doi: 10.1016/j.yexmp.2008.10.002. Epub 2008 Oct 30.
69	DAP10 contributes to CD8(+) T cell-mediated cytotoxic effector mechanisms during Mycobacterium tuberculosis infection.Immunobiology. 2011 May;216(5):639-47. doi: 10.1016/j.imbio.2010.09.010. Epub 2010 Sep 24.
70	IRGM gene polymorphisms and haplotypes associate with susceptibility of pulmonary tuberculosis in Chinese Hubei Han population.Tuberculosis (Edinb). 2016 Jan;96:58-64. doi: 10.1016/j.tube.2015.10.014. Epub 2015 Dec 8.
71	Analysis of IL1B, TAP1, TAP2 and IKBL polymorphisms on susceptibility to tuberculosis.Tissue Antigens. 2006 Apr;67(4):290-6. doi: 10.1111/j.1399-0039.2006.00566.x.
72	Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis.Tuberculosis (Edinb). 2008 Jul;88(4):335-43. doi: 10.1016/j.tube.2007.12.001. Epub 2008 Feb 19.
73	Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection.Front Microbiol. 2018 Jun 13;9:1267. doi: 10.3389/fmicb.2018.01267. eCollection 2018.
74	Correlation analysis between single nucleotide polymorphisms of pulmonary surfactant protein A gene and pulmonary tuberculosis in the Han population in China.Int J Infect Dis. 2014 Sep;26:31-6. doi: 10.1016/j.ijid.2014.03.1395. Epub 2014 Jun 28.
75	Cost-effectiveness of GeneXpert and LED-FM for diagnosis of pulmonary tuberculosis: A systematic review.PLoS One. 2018 Oct 29;13(10):e0205233. doi: 10.1371/journal.pone.0205233. eCollection 2018.
76	A genome-wide association study of pulmonary tuberculosis in Morocco.Hum Genet. 2016 Mar;135(3):299-307. doi: 10.1007/s00439-016-1633-2. Epub 2016 Jan 14.
77	Indicators for prediction of Mycobacterium tuberculosis positivity detected with bronchoalveolar lavage fluid.Infect Dis Poverty. 2018 Mar 24;7(1):22. doi: 10.1186/s40249-018-0403-x.
78	Serum amyloid A, protein Z, and C4b-binding protein chain as new potential biomarkers for pulmonary tuberculosis.PLoS One. 2017 Mar 9;12(3):e0173304. doi: 10.1371/journal.pone.0173304. eCollection 2017.
79	Association between CLEC4E gene polymorphism of mincle and pulmonary tuberculosis infection in a northern Chinese population.Gene. 2019 Aug 20;710:24-29. doi: 10.1016/j.gene.2019.05.011. Epub 2019 May 7.
80	Association of CTSZ rs34069356 and MC3R rs6127698 gene polymorphisms with pulmonary tuberculosis.Int J Tuberc Lung Dis. 2013 Sep;17(9):1224-8. doi: 10.5588/ijtld.12.0762. Epub 2013 Jul 3.
81	Comprehensive analysis of long non-coding RNAs expression pattern in the pathogenesis of pulmonary tuberculosis.Genomics. 2020 Mar;112(2):1970-1977. doi: 10.1016/j.ygeno.2019.11.009. Epub 2019 Nov 20.
82	Specific PIWI-interacting small noncoding RNA expression patterns in pulmonary tuberculosis patients.Epigenomics. 2019 Dec;11(16):1779-1794. doi: 10.2217/epi-2018-0142. Epub 2019 Nov 22.
83	Evaluation of a New IFN- Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting.Front Cell Infect Microbiol. 2017 Apr 11;7:117. doi: 10.3389/fcimb.2017.00117. eCollection 2017.
84	Age-dependent association between pulmonary tuberculosis and common TOX variants in the 8q12-13 linkage region.Am J Hum Genet. 2013 Mar 7;92(3):407-14. doi: 10.1016/j.ajhg.2013.01.013. Epub 2013 Feb 14.
85	Allelic variation in BTNL2 and susceptibility to tuberculosis in a South African population.Microbes Infect. 2007 Apr;9(4):522-8. doi: 10.1016/j.micinf.2007.01.011. Epub 2007 Jan 27.
86	Polymorphisms in CARD8 and NLRP3 are associated with extrapulmonary TB and poor clinical outcome in active TB in Ethiopia.Sci Rep. 2019 Feb 28;9(1):3126. doi: 10.1038/s41598-019-40121-8.
87	A novel role of Yin-Yang-1 in pulmonary tuberculosis through the regulation of the chemokine CCL4.Tuberculosis (Edinb). 2016 Jan;96:87-95. doi: 10.1016/j.tube.2015.10.013. Epub 2015 Nov 30.
88	Gene expression profiles of bronchoalveolar cells in pulmonary TB.Tuberculosis (Edinb). 2008 Jan;88(1):39-51. doi: 10.1016/j.tube.2007.07.003. Epub 2007 Oct 24.
89	1, 25-dihydroxyvitamin D(3) downregulates cytotoxic effector response in pulmonary tuberculosis.Int Immunopharmacol. 2018 Sep;62:251-260. doi: 10.1016/j.intimp.2018.07.018. Epub 2018 Jul 20.
90	Modulation of iron status biomarkers in tuberculosis-diabetes co-morbidity.Tuberculosis (Edinb). 2018 Jan;108:127-135. doi: 10.1016/j.tube.2017.11.011. Epub 2017 Nov 24.
91	Association of IL12RB1 polymorphisms with pulmonary tuberculosis in adults in Morocco.J Infect Dis. 2004 Aug 1;190(3):580-7. doi: 10.1086/422534. Epub 2004 Jul 6.
92	NRAMP1 D543N and INT4 polymorphisms in susceptibility to pulmonary tuberculosis: A meta-analysis.Infect Genet Evol. 2017 Oct;54:91-97. doi: 10.1016/j.meegid.2017.06.022. Epub 2017 Jun 22.
93	Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung.Am J Respir Crit Care Med. 1997 Mar;155(3):996-1003. doi: 10.1164/ajrccm.155.3.9117038.
94	Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis.BMC Infect Dis. 2019 Mar 19;19(1):268. doi: 10.1186/s12879-019-3881-y.
95	Human-Specific Mutations and Positively Selected Sites in MARCO Confer Functional Changes.Mol Biol Evol. 2018 Feb 1;35(2):440-450. doi: 10.1093/molbev/msx298.
96	AmpliSeq Screening of Genes Encoding the C-Type Lectin Receptors and Their Signaling Components Reveals a Common Variant in MASP1 Associated with Pulmonary Tuberculosis in an Indian Population.Front Immunol. 2018 Feb 20;9:242. doi: 10.3389/fimmu.2018.00242. eCollection 2018.
97	The effects of SP110's associated genes on fresh cavitary pulmonary tuberculosis in Han Chinese population.Clin Exp Med. 2016 May;16(2):219-25. doi: 10.1007/s10238-015-0339-4. Epub 2015 Jan 23.
98	Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene single nucleotide polymorphisms and its interaction with T2DM on pulmonary tuberculosis in Chinese Uygur population.Oncotarget. 2017 Jul 15;8(39):65601-65608. doi: 10.18632/oncotarget.19274. eCollection 2017 Sep 12.
99	Polymorphisms in SIGLEC1 contribute to susceptibility to pulmonary active tuberculosis possibly through the modulation of IL-1.Infect Genet Evol. 2017 Nov;55:313-317. doi: 10.1016/j.meegid.2017.09.031. Epub 2017 Sep 28.
100	The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of Mycobacterium tuberculosis and Anti-tuberculous Host Defense.Cell Host Microbe. 2017 Jan 11;21(1):59-72. doi: 10.1016/j.chom.2016.11.002. Epub 2016 Dec 22.
101	Evaluation of TLR2, TLR4, and TOLLIP polymorphisms for their role in tuberculosis susceptibility.APMIS. 2018 Jun;126(6):501-508. doi: 10.1111/apm.12855.
102	Genetic polymorphisms of CCL1 rs2072069 G/A and TLR2 rs3804099 T/C in pulmonary or meningeal tuberculosis patients.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12608-20. eCollection 2015.
103	Correlations between major risk factors and closely related Mycobacterium tuberculosis isolates grouped by three current genotyping procedures: a population-based study in northeast Mexico.Mem Inst Oswaldo Cruz. 2014 Sep;109(6):814-9. doi: 10.1590/0074-0276130550.
104	New variant identified in major susceptibility locus to tuberculosis on chromosomal region 8q12-q13 in Moroccan population: a case control study.BMC Infect Dis. 2017 Nov 7;17(1):712. doi: 10.1186/s12879-017-2807-9.